Cantor Fitzgerald Has Negative View of Amgen FY2025 Earnings

Key Points

• Cantor Fitzgerald has revised Amgen's FY2025 earnings per share estimate down to $21.30, slightly lower than their previous estimate of $21.35.
• The company's stock currently has a "Neutral" rating from Cantor Fitzgerald, with a price target set at $305.00.
• Amgen reported a 9.4% increase in revenue year-over-year, achieving $9.18 billion for the quarter, beating analyst expectations.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for Amgen in a report released on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the medical research company will post earnings per share of $21.30 for the year, down from their prior estimate of $21.35. Cantor Fitzgerald has a "Neutral" rating and a $305.00 price target on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the business posted $4.97 earnings per share. Amgen's revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.

A number of other analysts have also recently weighed in on the company. Citigroup raised their price target on Amgen from $310.00 to $315.00 and gave the company a "neutral" rating in a research note on Wednesday, September 24th. Morgan Stanley raised their price target on Amgen from $330.00 to $333.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Wall Street Zen cut Amgen from a "buy" rating to a "hold" rating in a research note on Saturday. UBS Group cut their price target on Amgen from $326.00 to $317.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 6th. Finally, William Blair reiterated an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and an average target price of $309.42.

Amgen Stock Down 1.8%

Amgen stock opened at $290.13 on Monday. Amgen has a 1-year low of $253.30 and a 1-year high of $335.88. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The stock has a market cap of $156.19 billion, a PE ratio of 23.72, a P/E/G ratio of 2.52 and a beta of 0.49. The stock's fifty day moving average is $286.77 and its two-hundred day moving average is $287.43.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fairvoy Private Wealth LLC boosted its stake in Amgen by 1.1% in the 2nd quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock worth $885,000 after purchasing an additional 35 shares during the period. Nicholson Wealth Management Group LLC boosted its stake in shares of Amgen by 0.6% during the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock worth $1,652,000 after buying an additional 35 shares during the last quarter. Crumly & Associates Inc. boosted its stake in shares of Amgen by 3.2% during the 2nd quarter. Crumly & Associates Inc. now owns 1,146 shares of the medical research company's stock worth $320,000 after buying an additional 36 shares during the last quarter. Maryland Capital Advisors Inc. boosted its stake in shares of Amgen by 5.2% during the 2nd quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company's stock worth $204,000 after buying an additional 36 shares during the last quarter. Finally, Lion Street Advisors LLC boosted its stake in shares of Amgen by 1.3% during the 2nd quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company's stock worth $774,000 after buying an additional 36 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.69% of the company's stock.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were issued a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen's payout ratio is presently 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.